Jacobs Levy Equity Management
DSGN icon

Jacobs Levy Equity Management’s Design Therapeutics DSGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18M Buy
565,597
+276,212
+95% +$3.44M 0.03% 347
2026
Q1 		$3.08M Buy
289,385
+94,774
+49% +$959K 0.01% 511
2025
Q4 		$1.83M Buy
+194,611
New +$1.52M 0.01% 596
2025
Q3 		– Sell
-13,501
Closed -$45.5K – 1003
2025
Q2 		$45.5K Sell
13,501
-3,981
-23% -$14.9K ﹤0.01% 1017
2025
Q1 		$67.5K Sell
17,482
-779
-4% -$3.72K ﹤0.01% 1054
2024
Q4 		$113K Sell
18,261
-262,010
-93% -$1.52M ﹤0.01% 916
2024
Q3 		$1.51M Sell
280,271
-195,987
-41% -$922K 0.01% 658
2024
Q2 		$1.6M Sell
476,258
-25,762
-5% -$100K 0.01% 645
2024
Q1 		$2.02M Sell
502,020
-47,098
-9% -$126K 0.01% 596
2023
Q4 		$1.46M Buy
+549,118
New +$1.26M 0.01% 658
2023
Q3 		– Sell
-16,100
Closed -$101K – 987
2023
Q2 		$101K Buy
+16,100
New +$98.5K ﹤0.01% 946

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jacobs Levy Equity Management's DSGN Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Design Therapeutics (DSGN) stake by 95% in Q2 2026, buying an estimated $3.44M and bringing the position to 565,597 shares worth $8.18M. The position accounts for 0.03% of the portfolio, ranked #347.

Jacobs Levy Equity Management first reported a position in DSGN in Q2 2023 and has held it in 11 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Jacobs Levy Equity Management held 565,597 shares of Design Therapeutics worth $8.18M as of Q2 2026.
  • Jacobs Levy Equity Management bought 276,212 Design Therapeutics shares in Q2 2026, an estimated $3.44M.
  • Design Therapeutics made up 0.03% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #347 holding.
  • Jacobs Levy Equity Management first reported a position in Design Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.